EP3426207A1 - Wundauflage in form eines selbstklebebandes - Google Patents

Wundauflage in form eines selbstklebebandes

Info

Publication number
EP3426207A1
EP3426207A1 EP16714484.9A EP16714484A EP3426207A1 EP 3426207 A1 EP3426207 A1 EP 3426207A1 EP 16714484 A EP16714484 A EP 16714484A EP 3426207 A1 EP3426207 A1 EP 3426207A1
Authority
EP
European Patent Office
Prior art keywords
fibers
polymers
nonwoven
dressing according
fiber
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP16714484.9A
Other languages
English (en)
French (fr)
Inventor
Jean-Marc Pernot
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Urgo Recherche Innovation et Developpement
Original Assignee
Urgo Recherche Innovation et Developpement
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Urgo Recherche Innovation et Developpement filed Critical Urgo Recherche Innovation et Developpement
Publication of EP3426207A1 publication Critical patent/EP3426207A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • D—TEXTILES; PAPER
    • D04—BRAIDING; LACE-MAKING; KNITTING; TRIMMINGS; NON-WOVEN FABRICS
    • D04H—MAKING TEXTILE FABRICS, e.g. FROM FIBRES OR FILAMENTARY MATERIAL; FABRICS MADE BY SUCH PROCESSES OR APPARATUS, e.g. FELTS, NON-WOVEN FABRICS; COTTON-WOOL; WADDING ; NON-WOVEN FABRICS FROM STAPLE FIBRES, FILAMENTS OR YARNS, BONDED WITH AT LEAST ONE WEB-LIKE MATERIAL DURING THEIR CONSOLIDATION
    • D04H1/00—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres
    • D04H1/40—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres from fleeces or layers composed of fibres without existing or potential cohesive properties
    • D04H1/42—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres from fleeces or layers composed of fibres without existing or potential cohesive properties characterised by the use of certain kinds of fibres insofar as this use has no preponderant influence on the consolidation of the fleece
    • D04H1/4391—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres from fleeces or layers composed of fibres without existing or potential cohesive properties characterised by the use of certain kinds of fibres insofar as this use has no preponderant influence on the consolidation of the fleece characterised by the shape of the fibres
    • D04H1/43918—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres from fleeces or layers composed of fibres without existing or potential cohesive properties characterised by the use of certain kinds of fibres insofar as this use has no preponderant influence on the consolidation of the fleece characterised by the shape of the fibres nonlinear fibres, e.g. crimped or coiled fibres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/02—Adhesive bandages or dressings
    • A61F13/0273—Adhesive bandages for winding around limb, trunk or head, e.g. cohesive
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/00051—Accessories for dressings
    • A61F13/00063—Accessories for dressings comprising medicaments or additives, e.g. odor control, PH control, debriding, antimicrobic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/01—Non-adhesive bandages or dressings
    • A61F13/01008—Non-adhesive bandages or dressings characterised by the material
    • A61F13/01017—Non-adhesive bandages or dressings characterised by the material synthetic, e.g. polymer based
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/24—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/26—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/58—Adhesives
    • A61L15/585—Mixtures of macromolecular compounds
    • D—TEXTILES; PAPER
    • D04—BRAIDING; LACE-MAKING; KNITTING; TRIMMINGS; NON-WOVEN FABRICS
    • D04H—MAKING TEXTILE FABRICS, e.g. FROM FIBRES OR FILAMENTARY MATERIAL; FABRICS MADE BY SUCH PROCESSES OR APPARATUS, e.g. FELTS, NON-WOVEN FABRICS; COTTON-WOOL; WADDING ; NON-WOVEN FABRICS FROM STAPLE FIBRES, FILAMENTS OR YARNS, BONDED WITH AT LEAST ONE WEB-LIKE MATERIAL DURING THEIR CONSOLIDATION
    • D04H1/00—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres
    • D04H1/40—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres from fleeces or layers composed of fibres without existing or potential cohesive properties
    • D04H1/42—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres from fleeces or layers composed of fibres without existing or potential cohesive properties characterised by the use of certain kinds of fibres insofar as this use has no preponderant influence on the consolidation of the fleece
    • D04H1/4326—Condensation or reaction polymers
    • D04H1/435—Polyesters
    • D—TEXTILES; PAPER
    • D04—BRAIDING; LACE-MAKING; KNITTING; TRIMMINGS; NON-WOVEN FABRICS
    • D04H—MAKING TEXTILE FABRICS, e.g. FROM FIBRES OR FILAMENTARY MATERIAL; FABRICS MADE BY SUCH PROCESSES OR APPARATUS, e.g. FELTS, NON-WOVEN FABRICS; COTTON-WOOL; WADDING ; NON-WOVEN FABRICS FROM STAPLE FIBRES, FILAMENTS OR YARNS, BONDED WITH AT LEAST ONE WEB-LIKE MATERIAL DURING THEIR CONSOLIDATION
    • D04H1/00—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres
    • D04H1/40—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres from fleeces or layers composed of fibres without existing or potential cohesive properties
    • D04H1/44—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres from fleeces or layers composed of fibres without existing or potential cohesive properties the fleeces or layers being consolidated by mechanical means, e.g. by rolling
    • D04H1/50—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres from fleeces or layers composed of fibres without existing or potential cohesive properties the fleeces or layers being consolidated by mechanical means, e.g. by rolling by treatment to produce shrinking, swelling, crimping or curling of fibres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F2013/00361—Plasters
    • A61F2013/00365—Plasters use
    • A61F2013/00463—Plasters use haemostatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/04—Materials for stopping bleeding

Definitions

  • a lesion located on capillaries will involve primary haemostasis that can stop the bleeding by forming a "platelet”.
  • Primary haemostasis will be enhanced by plasma coagulation, which will come into play to form an insoluble and solid fibrin clot.
  • This clot also serves as a matrix for the migration of cells involved in healing.
  • the mechanisms of fibrinolysis will allow clot dissolution, which is an obstacle to free vascular circulation.
  • Haemostatic products which promote or activate hemostasis, can intervene at several levels to help stop bleeding. The use of various haemostatic products has long been known to treat hemostasis.
  • Haemostatic products act mainly on haemostasis by reproducing the last stage of coagulation. Fibrinogen is transformed into fibrin, under the action of thrombin. Fibrinogen then divides into fibrin and fibrinopeptide monomers. The fibrin monomers aggregate and form a fibrin clot. Physiologically, the activated Factor XIII (FXIIIa) will stabilize the clot by creating internal bonds between the fibrin monomers. During wound healing, the increase in fibrinolytic activity is induced by plasmin, and the degradation of fibrin is initiated. The proteolytic degradation of fibrin can be inhibited by antifibrinolytics (tranexamic acid, aprotinin, etc.).
  • Hemostatic products with no specific action on the cascade of events occurring during coagulation will, in turn, contribute to stop bleeding, by acting nonspecifically on the different phases of hemostasis and coagulation.
  • collagen examples include collagen, gelatin, the combination of bovine thrombin with gelatin, alginates, oxidized cellulose, polysaccharides, aldehydes, cyanoacrylates or polyethylene glycols.
  • Collagen is a tissue protein found in the media of the wall of blood vessels. When vascular breccias appear, circulating platelets are exposed to collagen, adhere to these fibers and initiate their activation process. The contribution of exogenous collagen makes it possible, by increasing the adhesion surface, to promote this step, which results in the formation of the platelet nail and participates in the activation of the coagulation.
  • Gelatin is a collagen breakdown product that, in contact with blood, increases in volume and forms a gelatinous plug that fills the wound and mechanically opposes the flow of blood. Under the effect of the expansion of gelatin, the gel becomes saturated with blood, concentrates blood elements and promotes platelet activation. The physical matrix constituted by the gelatin network helps to stabilize the clot.
  • bovine thrombin with the gelatin matrix adds a direct action on the coagulation cascade.
  • the blood circulates between the gelatin granules and is locally exposed to high concentrations of thrombin, which intervenes to transform the fibrinogen of the patient into fibrin.
  • the exchange of Ca 2 + ions of the alginates against the Na + ions of the blood and exudate leads to the gradual transformation of the dry dressing into a gel.
  • the release of Ca2 + ions promotes platelet activation and fibrinogenesis.
  • the alginate fibers by their physical absorption capacity and their role of matrix participate in the formation of the clot.
  • hydrophilic microporous spherical particles of polysaccharides absorb the plasma by osmotic effect, form a gel which fills the wound and act by mechanical blocking of the blood flow.
  • the aldehydes act by forming an amide bond between two amino functions present on the amino acids of the tissue proteins and the aldehydes. These covalent bonds make it possible to create a stable bridging between the tissue proteins.
  • Cyanoacrylates are composed of various monomers which, under the action of a freshly mixed catalyst, polymerize and harden to form a tissue-adhering film and prevent bleeding by mechanical occlusion of blood flow.
  • Polyethylene glycols consist of precursors that, when mixed, polymerize to form a hydrogel. Anchorage of PEG particles to tissue proteins is provided by the formation of covalent bonds and creates a mechanical barrier.
  • a product according to the present invention In order to promote or activate hemostasis and particularly to promote or activate wound-related hemostasis, the use of a product according to the present invention has proved its effectiveness in treating and preventing prolonged bleeding. Indeed, it has been demonstrated that the product according to the present invention facilitates the coagulation of blood.
  • the dressing When used to stop bleeding, on a finger, for example, the dressing is in the form of a band is laid and wound with one or more turns depending on the strength of the desired band.
  • This dressing consists of a self-adhesive elastic band consists of a specific nonwoven which was obtained from short conjugated fibers which were crimped.
  • Nonwovens are generally textile materials that can not be used to make medical bandages or bandages because they are not elastic enough or stretchy. Also, have recently been developed nonwovens of curled fibers which have better properties of extensibility. Such products are described in the patent application WO 2008/015972, for their use as a retaining band or bandage, easily tearable.
  • this dressing has remarkable haemostatic properties which make it particularly suitable for use in the activation or the promotion of haemostasis.
  • the band included in the dressing according to the invention is advantageously self-adhesive.
  • the fibers constituting the band are advantageously crimped uniformly in the direction of the thickness of the nonwoven, and have a mean radius of curvature preferably between 10 and 200 microns.
  • the number of crimped fibers on the surface of the nonwoven is advantageously greater than 10 crimped fibers / cm.
  • the nonwoven preferably has a basis weight of between 10 g / m 2 and 300 g / m 2 .
  • the subject of the invention is a dressing comprising a strip consisting of a nonwoven of crimped fibers obtained from conjugated short fibers, in which
  • the nonwoven has a basis weight of between 10 g / m 2 and 300 g / m 2 , said fibers are uniformly crimped in the direction of the thickness of the nonwovens, and have an average radius of curvature of between 10 and 200 microns, and
  • the number of crimped fibers on the surface of the nonwoven is greater than 10 crimped fibers / cm 2 .
  • a variant of the present invention relates to a dressing which, in addition to the band, comprises at least one additional layer on one side of the nonwoven.
  • the fibers that have been used to make the nonwoven are preferably conjugated, polymeric in nature, and non-continuous (short).
  • the conjugate fibers in the sense of the invention are "latching friable" fibers having an asymmetric or laminated structure, which have the property of curling under the effect of heating. They owe this property to the difference of thermal contraction coefficient of the polymers which constitute them.
  • These fibers advantageously consist of at least two polymers which have a different coefficient of thermal contraction.
  • These polymers usually have softening points or different melting points. They may be chosen from thermoplastic polymers such as, for example: olefinic polymers (especially polymers of polyolefins C 2 -4 such as low and medium density polyethylenes and polypropylenes), acrylic polymers (especially acrylonitrile polymers with acrylonitrile units) such as acrylonitrile / vinyl chloride copolymers), vinylacetal polymers (especially polyvinyl acetal polymers), chlororovinyl polymers (especially polyvinyl chlorides, vinyl chloride / vinyl acetate copolymers and vinyl chloride / acrylonitrile copolymers) , chlorovinylidene polymers (especially vinylidene chloride / vinyl chloride copolymers and vinylidene chloride / vinyl acetate copolymers), styrenic polymers (especially heat-resistant polysty
  • non-adhesive polymers are preferred in wet heat (or water-resistant hydrophobic or non-water-soluble polymers). softening or melting point greater than or equal to 100 ° C, such as, for example, polypropylene polymers, polyester polymers and polyamide polymers. These polymers make it possible to avoid fiber bonding by melting or softening the fibers. Polyester aromatic polymers and polyamide polymers are particularly preferred for their excellent stability, heat resistance and ability to form fibers.
  • the fibers used are two-component.
  • the two-component fibers may be composed of polymers of the same chemical family or polymers of different chemical families, provided they have different thermal contraction coefficients.
  • the conjugated short fibers are bicomponent, the two components constituting them being polymers which have a softening point of greater than or equal to 100 ° C., said polymers being chosen from polypropylene polymers, polyester polymers and polyesters. or the polyamide polymers, and preferably are two different aromatic polyester polymers.
  • the two-component fibers consist of two polymers of the same chemical family: for example a homopolymer and a copolymer. It is indeed possible to lower the degree of crystallinity of the homopolymer, or even to make it amorphous, or to lower its melting point or its softening point, by copolymerizing the monomer with another.
  • the difference in melting point or softening point of the two polymers may be for example of the order of 5 to 150 ° C, preferably 50 to 130 ° C, and more preferably 70 to 120 ° C.
  • the proportion of copolymerizable monomer, relative to the total amount of monomers, is for example of the order of 1 to 50 mol%, preferably 2 to 40 mol%, and more preferably 3 to 30 mol% (particularly from 5 to 20 mol%).
  • the weight ratio of the homopolymer and the copolymer can be chosen according to the fiber structure; it is for example, in terms of the homopolymer (A) / copolymer (B) ratio, of the order of 90/10 to 10/90, preferably of 70/30 to 30/70, and more preferably of 60/40 to 40/60.
  • the bicomponent fibers consist of two aromatic polyester polymers and in particular the combination of a polyalkylene arylate homopolymer (a) and a polyalkylene arylate copolymer (b).
  • the polyalkylene arylate homopolymer (a) may be a homopolymer of an aromatic dicarboxylic acid (especially a symmetrical aromatic dicarboxylic acid such as terephthalic acid or naphthalene-2,6-dicarboxylic acid) and an alkane component diol (especially ethylene glycol or butylene glycol).
  • a polymer of the polyalkylene terephthalate series such as polyethylene terephthalate (PET) or polybutylene terephthalate (PBT) is used, and usually a PET with an intrinsic viscosity of the order of 0.6 to 0.7 used for manufacture of ordinary PET fibers.
  • PET polyethylene terephthalate
  • PBT polybutylene terephthalate
  • the polyalkylene arylate copolymer (b) can be obtained from a first monomer for the preparation of the polyalkylene arylate homopolymer (a), and a second monomer selected from a dicarboxylic acid such as a dicarboxylic acid an asymmetric aromatic, an alicyclic dicarboxylic acid, an aliphatic dicarboxylic acid, a longer chain alkane-diol component than the alkane diol of the polyalkylene arylate polymer (a), and / or a diol carrying an ether linkage.
  • a dicarboxylic acid such as a dicarboxylic acid an asymmetric aromatic, an alicyclic dicarboxylic acid, an aliphatic dicarboxylic acid, a longer chain alkane-diol component than the alkane diol of the polyalkylene arylate polymer (a), and / or a diol carrying an ether linkage.
  • an asymmetric aromatic dicarboxylic acid in particular isophthalic acid, phthalic acid or sodium 5-sulfoisophthalic acid,
  • an aliphatic dicarboxylic acid in particular a C 1-12 aliphatic dicarboxylic acid such as adipic acid,
  • alkane-diol in particular 1,3-propanediol, 1,4-butanediol, 1,6-hexanediol or neopentylglycol,
  • a polyoxyalkylene glycol especially diethylene glycol, triethylene glycol, polyethylene glycol or polytetramethylene glycol.
  • an asymmetric aromatic dicarboxylic acid such as isophthalic acid
  • a polyoxyalkylene glycol such as diethylene glycol
  • the polyalkylene arylate copolymer (b) may optionally be a hard segment elastomer of alkylene arylate (ethylene terephthalate, butylene terephthalate) and flexible segments for example of (poly) oxyalkylene glycol.
  • the proportion of dicarboxylic acid component intended to lower the melting point or the softening point relative to the total amount of dicarboxylic acid component is for example of the order of 1 to 50 mol%, preferably 5 to 50% by moles, and more preferably from 15 to 40% by moles.
  • the proportion of diol component intended to lower the melting point or the softening point, relative to the total amount of diol component is, for example, at most 30 mol%, and preferably at most 10 mol%, by example of the order of 0.1 to 10 mol%.
  • the cross section (perpendicular to the fiber length direction) of two-component fibers is not limited to the round shape (the ordinary form of solid fibers) and the modified shapes (flattened, elliptical, polygonal, 3- to 14-folate , T, H, V, dog bone (i), etc.), but may also be a hollow section.
  • the round section is usually chosen.
  • phased structures formed by a plurality of polymers for example the heart-shell, island and sea type structures, mixed, parallel (side-by-side or multilayer laminate), radial (radial laminate), hollow radial, block or random.
  • these structures it is preferred, for a more spontaneous development of thermal crimping, an eccentric heart-bark type structure or parallel type.
  • the core may consist of a polymer of the vinyl alcohol family such as an ethylene / vinyl alcohol copolymer or a polyvinyl alcohol, or a thermoplastic polymer having a melting point or a low softening point, for example a polystyrene or a low density polyethylene, provided that it allows crimping by having a thermal contraction coefficient deviation with the polymer constituting the bark.
  • a polymer of the vinyl alcohol family such as an ethylene / vinyl alcohol copolymer or a polyvinyl alcohol
  • a thermoplastic polymer having a melting point or a low softening point for example a polystyrene or a low density polyethylene
  • the two-component fibers have a side-by-side structure and consist of a first polymer which is a polyethylene terephthalate, and a second polymer which is a copolymer of an alkylene arylate with the isophthalic acid and / or diethylene glycol.
  • the average titer of the conjugated short fibers may for example be between 0.1 to 50 dtex, preferably between 0.5 and 10 dtex, and more preferably between 1 and 5 dtex (particularly between 1.5 and 3 dtex). ). If the title is too thin, not only are the fibers difficult to manufacture but they may lack strength. In addition, at the crimping stage, it is difficult to obtain beautiful serpentine crimps. If the title is too big, the fibers become stiff and make it difficult to develop sufficient crimping.
  • the average length of the conjugated short fibers before crimping may for example be between 10 and 100 mm, preferably between 20 and 80 mm, and more preferably between 25 and 75 mm (particularly between 40 and 60 mm). If the fibers are too short, in addition to the difficulty of forming the fiber web, entanglement of the fibers is insufficient in the crimping step and it is difficult to guarantee good strength and extensibility properties. If the fibers are too long, not only does it become difficult to form a web of uniformly weighted fibers, but the fibers become entangled excessively during the formation of the web, to the point of interfering with each other at the time of crimping and to prevent the development of extensibility.
  • the choice of the length of fiber in the aforesaid range allows some of the crimped fibers on the surface of the nonwoven to emerge moderately from said surface of the nonwoven and thus improve the non-woven self-adhesive which will be discussed later.
  • the average titer of the conjugated short fibers is between 1 and 5 dtex, preferably between 1.5 and 3 dtex, and the average length of the conjugated short fibers is between 10 and 100 mm, and preferably between 40 and 60 mm.
  • the application of a heat treatment to these conjugate fibers has the effect of developing the crimp and printing them embossed crimps in the form of coils (spiral or "coil spring").
  • the average radius of curvature of the crimped fibers in the sense of the invention corresponds to the average radius of curvature of the circles formed by the loops of the coils of the crimped fibers; it may be between 10 and 200 microns, for example between 10 and 250 microns, preferably between 20 and 200 microns, preferably between 50 and 160 microns, and more preferably between 70 and 130 microns.
  • the average radius of curvature of the crimped fibers can be determined by electron microscopy according to the following method.
  • a photograph (magnification ⁇ 100) of a nonwoven section is taken with a scanning electron microscope (SEM).
  • SEM scanning electron microscope
  • the fibers appearing on the plate one selects the fibers forming at least 1 spiral turn (serpentine) and one determines their radius of curvature like the radius of the circle traced along the spiral (radius of the circle when one observes the curly fiber in the direction of the axis of the coil).
  • the radius of curvature is determined as the half-sum of the large and small diameters of the ellipse.
  • the nonwoven according to the invention has the characteristic that the crimping of the conjugate fibers oriented approximately parallel to the planar direction is developed in a substantially uniform manner in the direction of thickness.
  • the number of fibers forming at least 1 spiral crimped turn is for example, in the central part (inner layer), from 5 to 50 by 5 mm (planar length) and 0.2 mm (thickness), preferably from 10 to 50 by 5 mm (planar) and 0.2 mm (thickness) and more preferably 20 to 50 per 5 mm (planar) and 0.2 mm (thickness).
  • the nonwoven Since most of the curled fibers have their axis oriented in the planar direction and the number of crimps is uniform in the direction of thickness, the nonwoven exhibits a high extensibility (without containing rubber or elastomer), and good operational resistance (without any adhesives).
  • areas delimited by a division into three equal parts in the direction of the thickness is meant the different areas obtained when cutting the nonwoven into three equal slices oriented perpendicular to the thickness.
  • the uniformity of the crimp in the direction of the thickness can be defined by the ratio of curvature of fiber.
  • fiber curl ratio is meant the ratio L2 / L1 of the length of the bilaterally stretched fiber L2 at the distance L1 of both ends of the fiber in the curled state.
  • This fiber curvature ratio (in particular in the central region in the direction of the thickness) is for example of the order of at least 1.3 (for example from 1.35 to 5), preferably from 1 to , 4 to 4 (for example from 1.5 to 3.5), and more preferably from 1.6 to 3 (particularly from 1.8 to 2.5).
  • the length of fiber L2 does not correspond to the length of the fiber that would be obtained if the three-dimensional curled fiber was stretched and rectilinearized. She corresponds to the length of fiber on the plate that is obtained when stretching and rectilinearizes the fiber appearing curly bidimensionally on the plate. In other words, the fiber length on the plate that is measured according to the invention is less than the actual fiber length.
  • the fiber curvature ratio is also uniform in the direction of the thickness.
  • the uniformity of the fiber curvature ratio can be evaluated by comparing, in a section taken in the direction of thickness, the fiber curl ratios obtained in the different layers delimited by a partition in three equal parts in the sense of thickness.
  • the nonwoven has in a section taken in the direction of the thickness, a fiber curvature ratio of greater than or equal to 1.3 in each of the areas delimited by a division into three equal parts in the sense of thickness, and the ratio of the minimum value to the maximum value of the fiber curl ratio in the different fields is greater than 75%.
  • the method of taking a photograph of the nonwoven section under the electron microscope and measuring the fiber curl ratio on selected areas within the different areas of sharing in three equal parts in the direction of thickness is carried out in each of the upper layers (recto domain), internal (central domain) and lower (backside domain), on domains which, in the direction of the length, are at least 2 mm, and in the direction of thickness, are positioned near the center of each layer and have the same thickness from one area to another.
  • these measurement domains are parallel in the direction of the thickness, and are defined such that each contains at least 100 fiber fragments allowing the measurement of their curvature ratio (of the order of preferably from minus 300, and more preferably from 500 to 1000).
  • the fiber curvature ratio of all the fibers in the domain is measured and the average value is calculated on each measurement domain, then the uniformity of the fiber curl ratio is calculated by comparing the domain showing the largest mean value and the domain showing the smallest mean value.
  • the measurement of the fiber curl ratio and its uniformity can be performed according to the following methodology. Take a photo (magnification ⁇ 100) of a section of non-woven fabric under an electron microscope and, in a part where the fibers appeared on the plate, the thickness is divided into three equal areas (front, inner and back layers), and near the center of each domain, measuring domains of at least 2 mm in the length direction and containing at least 500 measurable fiber fragments are defined. On these domains, we measure on the one hand the inter-end distance (the shortest distance) between the two ends of the fiber and on the other hand the fiber length (length of the fiber on the plate).
  • the fiber curvature ratio is calculated as the L2 / L1 ratio of the fiber length L2 to the inter-end distance L1 of the fibers. Then we calculate the average on each of the front, inner and back layers of the partition in three equal parts in the direction of the thickness. Finally, the uniformity of the fiber curvature ratio in the direction of the thickness is calculated from the ratio of its maximum and minimum values in the different layers.
  • FIGS. 4-a and 4-b of the patent application WO 2008/015972 The principle of the method of measurement of the fiber length is illustrated in FIGS. 4-a and 4-b of the patent application WO 2008/015972.
  • Fig.4- (a) illustrates the case of a fiber having one end emerging at the surface and the other end dipping into the nonwoven.
  • the inter-end distance L1 is here the distance from one end of the fiber to the dive boundary portion in the nonwoven.
  • the length of fiber L2 is the length obtained when the dimension of the observable fiber (part extending from the end of the fiber to the dive portion in the non-dimensional portion) is stretched bilaterally on the plate. woven).
  • Fig.4- (b) illustrates the case of a fiber whose two ends plunge into the nonwoven.
  • the inter-end distance L1 is here the distance of the two ends of the emerging portion to the surface of the nonwoven (ends on the plate).
  • the length of fiber L2 is the length obtained when two-dimensionally stretched, on the plate, the fiber in the part emerging on the surface of the nonwoven.
  • the average pitch of the coil is for example of the order of 0.03 to 0.5 mm, preferably of 0.03 to 0.3 mm, and more preferably of 0.05 to 0.2 mm.
  • the nonwoven may also contain fibers that are not bi-component fibers.
  • additional single-component fibers mention may be made, for example, of the polymer fibers already mentioned above, but also the cellulosic fibers such as, for example, natural fibers (wood wool, sheep's wool, silk, hemp), semi-synthetic fibers. synthetic (especially acetate fibers such as triacetate fibers) or regenerated fibers (rayon, lyocell).
  • the average titre and the average length of the single-component fibers are preferably identical to those of the two-component fibers. A single species can be used or several species of these single-component fibers can be combined.
  • regenerated fibers such as rayon fibers, semi-synthetic fibers such as acetate fibers, polyolefin fibers such as polypropylene or polyethylene fibers, and polyester fibers. and polyamide fibers.
  • the weight ratio between the two-component fibers and the single-component fibers is, for example, of the order of 80/20 to 100/0 (for example from 80/20 to 99/1), preferably from 90/10 to 100/0. and more preferably 95/5 to 100/0.
  • the nonwoven may also contain actives or additives such as stabilizers, UV filters, light stabilizers, antioxidants, antibacterials, deodorants, fragrances, dyes, fillers, antistatic agents, flame, plasticizers, lubricants, or crystallization retarders.
  • actives or additives such as stabilizers, UV filters, light stabilizers, antioxidants, antibacterials, deodorants, fragrances, dyes, fillers, antistatic agents, flame, plasticizers, lubricants, or crystallization retarders.
  • actives or additives such as stabilizers, UV filters, light stabilizers, antioxidants, antibacterials, deodorants, fragrances, dyes, fillers, antistatic agents, flame, plasticizers, lubricants, or crystallization retarders.
  • actives or additives such as stabilizers, UV filters, light stabilizers, antioxidants, antibacterials, deodorants, fragrances, dyes, fillers, antistatic agents, flame, plasticizers, lubricants, or crystallization retard
  • the assets are chosen from: anti-bacterials such as polymyxin B, penicillins (amoxycillin), clavulanic acid, tetracyclines, minocycline, chlorotetracycline, aminoglycosides, amikacin, gentamicin, neomycin, silver and its salts (Sulfadiazine argentic), probiotics;
  • anti-bacterials such as polymyxin B, penicillins (amoxycillin), clavulanic acid, tetracyclines, minocycline, chlorotetracycline, aminoglycosides, amikacin, gentamicin, neomycin, silver and its salts (Sulfadiazine argentic), probiotics;
  • antiseptics such as sodium mercurothiolate, eosin, chlorhexidine, phenylmercury borate, hydrogen peroxide, Dakin liquor, triclosan, biguanide, hexamidine, thymol, Lugol, Povidone iodine, Merbromine, Benzalkonium and Benzethonium Chloride, ethanol, isopropanol;
  • anti-virals such as Acyclovir, Famciclovir, Ritonavir;
  • anti fungal agents such as polyenes, Nystatin, Amphotericin B,
  • anti-pain agents such as paracetamol, codeine, dextropropoxyphene, tramadol, morphine and its derivatives, corticosteroids and derivatives;
  • anti-inflammatories such as glucocorticoids, nonsteroidal anti-inflammatory drugs, aspirin, ibuprofen, ketoprofen, flurbiprofen, diclofenac, aceclofenac, ketorolac, meloxicam, piroxicam, tenoxicam, Naproxen, Indomethacin, Naproxcinod, Nimesulide, Celecoxib, Etoricoxib, Parecoxib, Rofecoxib, Valdecoxib, Phenylbutazone, Niflumic acid, Mefenamic acid, Beta-18-glycyrrhetinic acid;
  • - restructuring assets for example rescutants of dander
  • rescutants of dander such as silica derivatives, vitamin E, chamomile, calcium, horsetail extract, silk Lipester
  • anesthetics such as benzocaine, lidocaine, dibucaine, pramoxine hydrochloride, bupivacaine, mepivacaine, prilocaine and etidocaine.
  • haemostatics such as fibrinogen, factor XIII, fibronectin, thrombin, bovine aprotinin, tranexamic acid, collagen, aldehydes, cyanoacrylates, polyethylene glycol, alginates, cellulose, polysaccharides.
  • the other mechanical properties of the nonwoven will preferably be as follows.
  • the thickness of the nonwoven fabric is advantageously between 0.25 and 5 mm, preferably between 0.4 and 2.5 mm and very particularly between 0.5 and 1.5 mm.
  • the thickness can be measured according to EN 9073-2.
  • the self-adhesion of the web according to the invention is achieved by the presence of many fibers in the partially free state on the surface of the nonwovens, the surface fibers becoming entangled with each other at the time of the superimposition of the web on it. -even.
  • the number of crimped fibers, in particular in the form of a coil or a loop, on the surface of the nonwoven is advantageously greater than 10 crimped fibers / cm 2. and preferably between 10 and 50 crimped fibers / cm 2 .
  • a number of crimped fibers on the nonwoven surface of between 10 and 35 crimped fibers / cm 2 will be preferred.
  • the number of crimped fibers on the surface of the nonwoven can be determined as follows.
  • the self-adhesion characterization of the band is evaluated visually.
  • a strip of nonwoven having a width of 15 mm is wound by stretching it slightly on the fingertip so as to form three turns and then torn manually.
  • the self-gripping power is then estimated. It follows from this test that the bands remain on the finger for at least 30 minutes.
  • This additional layer makes it possible to improve, if necessary, the properties of the self-adhesive elastic band, for example by adapting its absorption, damping, conformability, rigidity or occlusivity capacities.
  • materials based on synthetic or natural fibers we can mention woven fabrics, nonwovens, knits, 3D knits, films, foams and their combinations.
  • the additional layer may optionally contain active agents that contribute to improving the healing of the wound or that can reduce the pain, or antibacterial agents.
  • active agents that contribute to improving the healing of the wound or that can reduce the pain, or antibacterial agents.
  • antibacterial fibers for example silver fibers
  • an antibacterial agent for example triclosan.
  • the example uses a nonwoven, based on two-component asymmetric crimped fibers, manufactured according to the teaching of the patent application WO 2008/015972.
  • This nonwoven can be reference SR 0046 from Kuraray.
  • This nonwoven is made from the side-by-side fiber, based on polyester copolymers of the company Kuraray whose reference is PN-780.
  • the performance of dressings consisting of a web of nonwoven according to the invention on the coagulation of blood was evaluated.
  • Whole sheep blood was contacted with a nonwoven web according to the invention at a ratio of 1 cm 2 / mL in test tubes incubated at 37 ⁇ 1 ° C.
  • a control tube without tape is tested under the same conditions as a negative control.
  • the test tubes are gently inverted every minute until a blood clot is observed.
  • the coagulation time is recorded for the article tested (4 trials).
  • the average coagulation time of the sheep blood in the presence of the nonwoven according to the invention was 13 minutes thirty seconds.
  • the mean clotting time of the sheep blood in the control test tube was about 26 minutes thirty seconds.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Textile Engineering (AREA)
  • Materials Engineering (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Mechanical Engineering (AREA)
  • Medicinal Chemistry (AREA)
  • Nonwoven Fabrics (AREA)
EP16714484.9A 2016-03-08 2016-03-08 Wundauflage in form eines selbstklebebandes Withdrawn EP3426207A1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/FR2016/050529 WO2017153640A1 (fr) 2016-03-08 2016-03-08 Pansement se présentant sous la forme d'une bande autoadhérente

Publications (1)

Publication Number Publication Date
EP3426207A1 true EP3426207A1 (de) 2019-01-16

Family

ID=55661475

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16714484.9A Withdrawn EP3426207A1 (de) 2016-03-08 2016-03-08 Wundauflage in form eines selbstklebebandes

Country Status (3)

Country Link
EP (1) EP3426207A1 (de)
FR (1) FR3048607A1 (de)
WO (1) WO2017153640A1 (de)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101065094B1 (ko) * 2002-11-21 2011-09-16 인비스타 테크놀러지스 에스.에이.알.엘 높은 신장회복률을 갖는 부직포 및 그의 제조방법
ES2446246T3 (es) * 2006-08-04 2014-03-06 Kuraray Co., Ltd. Material textil no tejido estirable y bandas
US8329211B2 (en) * 2010-05-17 2012-12-11 Ethicon, Inc. Reinforced absorbable multi-layered fabric for hemostatic applications
US8273369B2 (en) * 2010-05-17 2012-09-25 Ethicon, Inc. Reinforced absorbable synthetic matrix for hemostatic applications
FR2994833B1 (fr) * 2012-09-03 2014-09-19 Urgo Lab Nouvelle bande elastique aux proprietes de contention optimisees

Also Published As

Publication number Publication date
WO2017153640A1 (fr) 2017-09-14
FR3048607A1 (fr) 2017-09-15

Similar Documents

Publication Publication Date Title
CA2832885C (fr) Pansement adhesif mince tres absorbant, ses utilisations pour le traitement des plaies chroniques
JP2010520377A (ja) 不織繊維布帛
CA2878869C (fr) Pansement a liberation prolongee d'actifs
CH625702A5 (de)
EP2892483B1 (de) Neuartige elastische bandage mit verbesserten stützeigenschaften
EP2892482B1 (de) Neuartige selbstklebende elastische bandage, insbesondere zur behandlung und prävention von venenerkrankungen
WO2013153225A1 (fr) Poudre formant pansement et materiau absorbant correspondant
EP3426207A1 (de) Wundauflage in form eines selbstklebebandes
EP2892484B1 (de) Elastische bandage, insbesondere zur behandlung und prävention von venenerkrankungen
FR2959418A1 (fr) Pansement ampoule comprenant une masse adhesive hydrocolloide
EP3082887B1 (de) Verbundwerkstoff zum füllen von hohlraumwunden
FR3030225A1 (fr) Pansement comprenant un support et une matrice elastomerique hydrophobe
WO2015092314A1 (fr) Matériau composite de remplissage des plaies cavitaires
EP3515386B1 (de) Saugfähiger wundverband mit einem in wasser auflösbarem, superabsorbierendem vliesstoff
FR3048617B1 (fr) Pansement adapte aux peaux sensibles
FR3068882B1 (fr) Pansement interface
WO2017017386A1 (fr) Pansement comprenant un support et une matrice elastomerique hydrophobe.

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20180904

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20220218

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20230620